Objective
Non-neoplastic lung diseases (NNLD), such as COPD and interstitial lung diseases rank second among the causes of death and NNLD appear as a growing EU wide challenge. They are characterized by irreversible remodeling with a relentless loss of lung function and a 5-year survival of only 30%. This dysfunctional reaction to injury can be triggered by particulate matters with macrophages (MO) as the key regulators. Wholesale therapeutic suppression of the inflammome actually increases the risk of death, whereas targeted therapy of signalling cascades by novel pharmaceuticals, e.g. nintedanib, only slows disease progression. Thus lung transplantation remains the ultima ratio. However, available grafts are limited, treatment costs are high and the 5-year survival barely surpasses 50%. Therefore novel approaches to understand, prevent and ultimately cure NNLDs are urgently needed. Towards this goal my group focusses on both, the main effector cell in NNLD, the myofibroblast, and the inflammome and particularly MOs, as these orchestrate both, lung healing and remodeling. Modulating the pulmonary immune system, rather than subduing it, holds significant promise. To this end, we have to understand the very early events in NNLDs. There are 2 major obstacles for efficient research: i) the lack of adequate animal models and ii) the availability of human specimens. Therefore we established a unique platform for NNLD: we utilize fresh explanted human lungs from Europe’s largest LuTx program and set up a singular 24h/7d workflow, ensuring short ischemia and tissue viability. In the last years, we have worked up over 500 lungs, acted as an international multiplier for pulmonary research, patented new imaging techniques and described novel diseases. Our understanding MO biology in NNLDs showed us the great potential in macrophages. Now we are going to use these macrophages as potential therapeutics. Hereby we will make a difference in translational medicine in Europe and the world.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.1.1. - EXCELLENT SCIENCE - European Research Council (ERC)
MAIN PROGRAMME
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
ERC-COG - Consolidator Grant
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) ERC-2017-COG
See all projects funded under this callHost institution
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
30625 Hannover
Germany
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.